Background: Rosuvastatin (RSV) is a potent statin with a lower potential for drug
interactions. However, recent data have revealed unexpected increases in RSV …

Background Lopinavir/ritonavir-containing antiretro-viral therapy can cause hyperlipidaemia.
However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin …

Objectives: This open-label, single-arm, pharmacokinetic (PK) study in HIV-seronegative
volunteers evaluated the bioequivalence of rosuvastatin and lopinavir/ritonavir when …

Background Rosuvastatin is a new 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA)
reductase inhibitor. Itraconazole, an inhibitor of cytochrome P450 (CYP) 3A4 and the …

Background: Rosuvastatin, a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor
(“statin”), has been marketed for the treatment of patients with dyslipidemia. Objectives: The …

Background: Rifampicin (rifampin) has been reported to have drug-drug interaction with
several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors due to its ability to …

Background: Cross-study comparisons suggest that systemic exposure (AUC) to
rosuvastatin calcium, a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor, may be …

Background: Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor
developed for the treatment of dyslipidemia. The results of clinical trials suggest that it is …

To identify pharmacokinetic (PK) drug-drug interactions between tipranavir-ritonavir (TPV/r)
and rosuvastatin and atorvastatin, we conducted two prospective, open-label, single-arm …

HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management
of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern …